Background: Sildenafil was the first selective drug available on the market as oral therapy for erectile dysfunction (ED). A novel sildenafil orodispersible film (ODF) for ED treatment, containing sildenafil citrate, has recently been marketed.
Objectives: Study objective was to investigate sildenafil bioavailability of the novel ODF formulation after sublingual and supralingual administration.
Methods: In this randomised, two-way cross-over study, 12 healthy male volunteers received a single 50 mg sildenafil dose by the sublingual and supralingual administration routes. Plasma sildenafil was determined up to 12 h post-dose. Peak concentration (C) and area under concentration-time curve (AUC) were calculated and compared between the two administration routes by analysis of variance (ANOVA).
Results: Sublingual and supralingual administration can be claimed equivalent regarding the extent of sildenafil exposure since AUC 90 % CIs corresponded to 94.90-110.58% and were within the pre-specified acceptance range. C 90% CIs (79.92-125.57%) were only slightly outside the 80.00-125.00% limits, due to the small sample size, while the time to achieve C did not differ between treatments (p = 0.9277). Rate of exposure of the two administration routes was therefore similar. Reported treatment-related adverse events were mild to moderate headache (33.3% of subjects) and vomiting (8.3%).
Conclusions: In healthy men, sublingual and supralingual administration of sildenafil ODF resulted in a remarkably similar pharmacokinetic profile and confirmed the safety of both study treatments. The recently marketed sildenafil ODF, administered by both investigated routes, can provide a valuable alternative to the marketed solid oral forms (tablets) in ED treatment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6061399 | PMC |
| http://dx.doi.org/10.1007/s40261-018-0665-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Bioequivalence of rimegepant, a small molecule CGRP receptor antagonist, administered as an oral tablet, a sublingual orally disintegrating tablet, and a supralingual orally disintegrating tablet: two phase 1 randomized studies in healthy adults.
Cephalalgia
February 2024
Albert Einstein College of Medicine, Bronx, NY, USA.
Article Synopsis
- Rimegepant is a medication used for treating migraines and can be taken as a disintegrating tablet or standard oral tablet.
- Two studies were conducted to compare how well the sublingual (under the tongue) and supralingual (above the tongue) forms of rimegepant absorbed into the body compared to the oral tablet.
- Results showed that both forms of rimegepant were bioequivalent to the oral tablet, meaning they are absorbed at similar rates and effectively achieve the desired concentration in the bloodstream.
Physiologically Based Pharmacokinetic Modeling to Understand the Absorption of Risperidone Orodispersible Film.
Front Pharmacol
February 2020
National Pharmaceutical Engineering Research Center, China State Institute of Pharmaceutical Industry, Shanghai, China.
Objective: The aim of the present study was to investigate the absorption routes as well as the potential application of the oral transmucosal delivery of risperidone orodispersible film (ODF) using physiologically based pharmacokinetic modeling.
Methods: The pharmacokinetic study after intragastric (i.g.
Pharmacokinetics of a Novel Sildenafil Orodispersible Film Administered by the Supralingual and the Sublingual Route to Healthy Men.
Clin Drug Investig
August 2018
CROSS Research S.A., Via F.A. Giorgioli 14, 6864, Arzo, Switzerland.
Background: Sildenafil was the first selective drug available on the market as oral therapy for erectile dysfunction (ED). A novel sildenafil orodispersible film (ODF) for ED treatment, containing sildenafil citrate, has recently been marketed.
Objectives: Study objective was to investigate sildenafil bioavailability of the novel ODF formulation after sublingual and supralingual administration.
Both sublingual and supralingual routes of administration are effective in long-term allergen-specific immunotherapy.
Allergy Asthma Proc
September 2011
Department of Immunology and Allergology, Charles University, Medical Faculty in Pilsen, Czech Republic.
The aim of this study was to confirm or refute the difference between efficacy of long-term specific immunotherapy (SIT) with standardized allergen vaccine consisting of six grass pollens (oat grass, orchard grass, fescue, rye grass, timothy grass, and rye) administered either by sublingual or by supralingual route. To investigate clinical and immunologic changes, 51 patients of a previous 1-year double-blind, placebo-controlled, randomized study were enrolled in an open randomized study that continued over the next 3 years. Sublingual or supralingual immunotherapy (SLIT) was performed in the same way, keeping the drops under or on the tongue, respectively, for 1-2 minutes before swallowing them.
View Article and Find Full Text PDFEffect of absorption site on the pharmacokinetics of sublingual asenapine in healthy male subjects.
Biopharm Drug Dispos
July 2010
Merck Sharp & Dohme, Oss, The Netherlands.
Asenapine is a psychopharmacologic agent approved in the United States for the acute treatment of schizophrenia in adults and the acute treatment of manic or mixed episodes associated with bipolar I disorder with or without psychotic features in adults. It is pending approval for the treatment of schizophrenia and manic episodes associated with bipolar I disorder in Europe. Asenapine is administered as a sublingual formulation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!